EP2753187
METHOD FOR PREVENTING AND/OR TREATING INSULIN RESISTANCE
Hover an owner to see their dates
- Caelus Pharmaceuticals B.V.; Stichting Amsterdam UMCsince Feb 16, 2024
- Caelus Pharmaceuticals B.V.; Academisch Medisch CentrumJul 11, 2014 – Feb 16, 2024
- Academisch Medisch Centrum; Wageningen UniversiteitJun 13, 2014 – Jul 11, 2014
The present invention describes use of Eubacterium hallii etrel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria, as a medicament, in particular for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitusas well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes)in a subject in need thereof, said method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
From the international application WO2013032328
| Date | Case | Division | Type | Outcome | Parties |
|---|---|---|---|---|---|
| May 11, 2026 | UPC CFI 1615/2026 | The Hague LD | Provisional measures | Locked | CAELUS LIFESCIENCES IP B.V. +5 |
Additional proceedings on this patent